Journal issues > Issue 5, September 2022 > Highlights in Chronic Lymphocytic Leukaemia

Highlights in Chronic Lymphocytic Leukaemia

SUMMARY

Chronic lymphocytic leukaemia (CLL) is a rapidly progressing field in haemato-oncology. The EHA 2022 meeting again provided an update on major clinical trials, the prognostic impact of TP53 mutation in the era of BCL2inh, new insights into the role of marrow microenvironment in the course of the disease, new approaches to Richter’ syndrome and many new promising drugs. The oral presentations about this topic, with practical importance for the clinicians, are covered in this article.

(BELG J HEMATOL 2022;13(5):200–6)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top